Core Viewpoint - The company, He Yuan Bio, is navigating through a challenging period in the biopharmaceutical industry by focusing on technological barriers and production efficiency as key factors for sustainable growth [1] Group 1: Financial Performance - In the first half of 2025, He Yuan Bio reported a revenue of 119.85 million yuan, representing a year-on-year growth of 6.01% [1] - The net profit attributable to the parent company was -104.57 million yuan, a decrease in loss of 8.78 million yuan compared to the same period last year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -104.51 million yuan, a decrease in loss of 14.90 million yuan year-on-year [1] Group 2: Business Development - The CRO business segment achieved sales revenue of 40.70 million yuan, a year-on-year increase of 3.79%, serving over 14,000 research laboratory clients [2] - The CDMO business maintained its leading position with sales revenue of 65.62 million yuan, remaining stable compared to the previous year [2] - The company assisted clients in obtaining 52 domestic and international IND approvals and undertook over 540 CDMO projects, with new orders exceeding 90 million yuan in the year [2] Group 3: Regenerative Medicine Progress - He Yuan Bio has made significant advancements in regenerative medicine, including the development of processes for stem cells and immune cells [3] - The company’s subsidiary, He Yuan He Mei, successfully registered human dermal fibroblast exosomes in the global cosmetics ingredient directory, expanding its market opportunities [3] - The company is enhancing its production capacity at its Lingang industrial base, which is now fully operational, positioning itself among the top in the international industry [3] Group 4: R&D and Technological Innovation - In the first half of 2025, He Yuan Bio invested 23.21 million yuan in R&D, accounting for 19.37% of its revenue, and filed for 10 new patents [4] - The company is leveraging AI technology to enhance research and production efficiency, developing an intelligent R&D system that integrates AI with production data [5] - The AI models developed by the company are being applied across various R&D projects, significantly improving efficiency [5] Group 5: Market Outlook - Despite the current adjustment period in the CGT CDMO industry, the long-term growth potential remains intact, with projections indicating that the global and Chinese CGT CDMO market will reach $27.45 billion and $4.48 billion by 2030, respectively [6] - The company is expected to strengthen its competitive edge through optimized capacity and order growth, combined with deep integration of technology and AI [6] - As the biopharmaceutical industry improves, He Yuan Bio is poised to accelerate its growth potential in the cell and gene therapy sector [6]

Core Viewpoint - The company reported a revenue of 120 million yuan for the first half of 2025, reflecting a year-on-year growth of 6.01%, but continued to incur a net loss of 105 million yuan, although this was an improvement compared to a loss of 113 million yuan in the same period last year [1]. Financial Performance - Revenue for the first half of 2025 reached 120 million yuan, marking a 6.01% increase year-on-year [1]. - The net profit attributable to shareholders was -105 million yuan, an improvement from -113 million yuan in the previous year [1]. - Basic earnings per share were -0.163 yuan [1]. Business Operations - The company's cell and gene therapy CDMO business faced challenges due to macroeconomic changes, industry conditions, and downstream demand [1]. - The execution order prices for the CDMO business remained at a low level [1]. - The operational costs, including depreciation, energy consumption, and administrative expenses, were relatively high, contributing to the overall loss [1]. - The gross profit margin for the cell and gene therapy CDMO business remained negative [1].

公司代码：688238 公司简称：和元生物 和元生物技术（上海）股份有限公司2025 年半年度报告 1 / 195 和元生物技术（上海）股份有限公司 2025 年半年度报告 和元生物技术（上海）股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 本公司已在本半年度报告中详细阐述在生产经营过程中可能面临的相关风险，敬请查阅第三 节"管理层讨论与分析"之"四、风险因素"部分的相关内容。公司提请投资者特别关注如下风 险： 报告期内，公司细胞和基因治疗 CDMO 业务继续受宏观环境变化、产业状况、下游需求等因 素影响，执行订单价格仍处于较低水平，而公司临港产业基地产能释放需要时间，折旧摊销成本、 能耗成本、行政办公费用等运营成本费用相对较高，截止目前细胞和基因治疗 CDMO 业务营业毛 利率仍为负值，公司整体仍处于亏损状态，但较上年度同期有所改善。 细胞和基因治疗是生物医药行业未来的重点发展方向，国家和地方不同层级产业政策持续给 予大力支持，随着国内外投 ...

Core Viewpoint - The company reported a slight increase in revenue for the first half of 2025, but continued to face significant net losses [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 120 million, representing a year-on-year increase of 6.01% [2] - The net loss attributable to shareholders for the same period was approximately 105 million [2] - Basic earnings per share for the first half of 2025 were a loss of 0.163 [2] - In comparison, the revenue for the same period in 2024 was approximately 113 million, with a net loss of about 113 million and a basic earnings per share loss of 0.175 [2]

证券代码：688238 证券简称：和元生物 公告编号：2025-058 和元生物技术（上海）股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 8 月 20 日(星期三)至 8 月 26 日(星期二)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zhengquanbu@obiosh.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 和元生物技术（上海）股份有限公司（以下简称"公司"）已于 2025 年 8 月 19 日披露公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解 公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 8 月 27 日(星期三) 下午 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交 流。 一、说明会类型 本次业绩说明会以网络互动形式召 ...

为践行以"投资者为本"的上市公司发展理念，维护公司全体股东利益，增 强投资者信心，促进公司健康可持续发展，和元生物技术（上海）股份有限公司 （以下简称"公司"）基于对公司未来发展前景的信心及内在价值的认可，结合 自身发展战略和经营情况，于 2025 年 5 月制定了公司 2025 年度"提质增效重回 报"专项行动方案（以下简称"行动方案"）。2025 年上半年，公司根据行动方 案内容积极开展和落实相关工作，现将 2025 年上半年行动方案的主要执行进展 情况报告如下： 一、聚焦主营业务，提升核心竞争力 2025 年上半年，国内生物医药领域机遇与挑战交织并存，呈现出多元化发 展与市场激烈竞争的复杂态势，公司坚守"客户第一""守正创新"的核心经营 理念，聚焦细胞和基因治疗 CRO/CDMO 主营业务，以乐观稳健的姿态应对外部变 化。各事业部锚定年初经营目标和提质增效重点方向，持续高效推进客户资源储 备和品牌影响力，积极推行各项行动方案，不断练好内功，提升运营管理能力， 为业务的长远发展筑牢根基。 报告期内，公司实现营业收入 11,985.50 万元，较上年同期增幅 6.01%；实 现归属于母公司所有者的净利润-1 ...

和元生物技术（上海）股份有限公司 第四届董事会独立董事专门会议第一次会议资料 和元生物技术（上海）股份有限公司 第四届董事会独立董事专门会议第一次会议决议 会议时间：2025 年 8 月 15 日上午 9:00-9:15 会议地点：上海市临港新片区沧海路 3888 号 召集人：独立董事高国垒先生 主持人：独立董事高国垒先生 经审议，独立董事认为：公司 2025 年半年度募集资金存放、管理与实际使 用情况，符合《上市公司募集资金监管规则》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关规定，公司对募集资金采用了专户存 储，专款专用，并及时履行了相关信息披露义务，募集资金的存放、管理与使用 情况同公司募集资金相关信息披露的内容一致，不存在违规使用募集资金的行为， 不存在损害公司和全体股东特别是中小股东利益的情况。 2、议案表决结果： 和元生物技术（上海）股份有限公司 第四届董事会独立董事专门会议第一次会议资料 同意票数 4 票，反对票数 0 票，弃权票数 0 票，回避票数 0 票。 和元生物技术（上海）股份有限公司（以下简称"公司"）第四届董事会独 立董事专门会议第一次会议于 2025 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-057 和元生物技术（上海）股份有限公司 关于 2025 年半年度募集资金存放、管理与实际使用 情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公 司募集资金监管规则》（以下简称"《监管规则》"）和上海证券交易所发布的《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》（以下简称 "《规范运作》"）等有关规定，和元生物技术（上海）股份有限公司（以下简称 "公司"）董事会编制了《2025 年半年度募集资金存放、管理与实际使用情况的 的专项报告》，具体如下： 一、募集资金基本情况 (一)实际募集资金的金额及到账情况 根据中国证监会于 2022 年 1 月 11 日出具的《关于同意和元生物技术（上海） 股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕61 号），并经 上海证券交易所同意，公司向社会公开发行人民币普通股（A 股）100,000,000 股，每股 ...

和元生物公告，2025年上半年营业收入1.2亿元，同比增长6.01%。归属于上市公司股东的净亏损1.05亿 元，上年同期净亏损1.13亿元。 ...

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].